ResearchMoz

JustPharmaReports.com Market Research Reports

Publications by Justpharmareports provide clear, comprehensive, up-to-date, practical information and analyses on pricing/ reimbursement and medicines’ distribution for the industry professional. Researched and written exclusively by Donald Macarthur, probably the world's most experienced author of reports on the global pharmaceutical business environment, with more than 70 major titles over 25 years to his name, the detailed but readable texts will save $000s in consultants' fees alone.

List of reports from JustPharmaReports.com

Displaying 1 to 8 (of 8 records)
Orphan Drugs in Europe: Pricing, Reimbursement, Funding and Market Access Issues, 2013 Edition
Oct 2013  
The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget...
$2350
Risk Sharing and Other Forms of Managed Entry Agreements for Medicines, Worldwide
Feb 2013  
Managed entry agreements apply to an increasing number of new, innovative drugs in a growing number of markets. They are designed to share the risk between the manufacturer and the payer, consequent on uncertainties - usually at launch - about the product’s value (clinical- and cost-effectiveness), budget impact and/or utilisation to optimise performance, whilst at the same time...
$1050
Pharmaceutical Pricing & Distribution in Japan, 2012 Update
Jun 2012  
No serious pharmaceutical company can afford to ignore Japan, a $120 billion market, the second-largest in the world. It remains a tough and highly competitive market to crack, however, with the environment for developing and marketing medicines dominated by price.  No new brand can be introduced without a yakka (reimbursement price) set by the  government....
$1400
Biosimilars: Current Situation & Future Prospects, Worldwide
Mar 2012  
The engine of the biosimilar sector is the same as with small molecule drugs, patent expiry. On this basis, prospects for biosimilars look good, with the vast majority of leading originator brands in the global biologics market expected to lose some degree of protection by 2019. All major countries now make provision for an abbreviated biosimilar development and regulatory...
$3000
Pharmaceutical Pricing & Distribution in Japan, 2010 Update
Oct 2011  
The author’s 2008 major title ‘Pharmaceutical Pricing & Distribution in Japan’ was described by PhRMA Japan as ‘a superb report…to understand Japan there is nothing better’. His new report packs all the essentials needed to optimise market access and life cycle management into 60 pages and offers tremendous value. Completely updated, it...
$760
Orphan Drugs in Europe: Pricing, Reimbursement, Funding & Market Access Issues, 2011 Edition
Jun 2011  
The cost of treating rare disease in an age when austerity measures are hitting total healthcare funding across Europe is a highly controversial, even emotive subject. There is a clear and pressing clinical need, a strong patient voice and the treatments themselves sometimes offer the only hope. But is this enough to assure premium prices and special status in an era of budget...
$2300
Market Access Korea: Breaking into the Developed World's Fastest Growing Pharmaceutical Market
Nov 2010  
South Korea as a country has been an economic success story and the origin of much cutting edge technology, but its pharmaceutical market can now also be given ‘Asian tiger’ status. The past four years have seen total sales growth of 15.6%, 13.5%, 12.4% and 13.8% respectively. IMS forecasts CAGR of 6.5% from 2010 through 2015, making Korea the fastest growing developed market...
$1380
Orphan Drugs in Asia-Pacific: From Designation to Pricing, Funding & Market Access
Feb 2010  
A major new report Orphan Drugs in Asia-Pacific: From designation to pricing, funding and market access focuses on five developed markets in the region: Japan, South Korea, Taiwan, Singapore and Australia. Each has passed specific measures to promote the development, registration and/or commercialisation of rare disease treatments. Singapore’s Medicines (Orphan Drug) Exemption...
$2320
 
Displaying 1 to 8 (of 8 records)

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.com

Popular Publishers

Transparency Market Research
ICD Research
Technavio
 
GBI Research
Winter Green Research
GlobalData